The goal of this clinical trial is to evaluate the effectiveness of an anti-inflammatory dietary intervention on physical health, mental health, and cognitive functioning in individuals with clinically diagnosed anxiety and/or depression, and to assess the agreement between artificial intelligence-based analysis of verbal and non-verbal language patterns and standard psychometric assessment tools. The study will include adult participants (≥18 years) with a clinical diagnosis of anxiety and/or depressive disorder, irrespective of sex or gender. The main questions it aims to answer are: Does a 4-month anti-inflammatory dietary intervention improve mental health outcomes (anxiety and depressive symptoms) compared to a control condition in individuals with anxiety and/or depression? Does the intervention lead to improvements in physical health and cognitive functioning relative to the control group? Are verbal and non-verbal language patterns analyzed using artificial intelligence coherent with the results obtained from validated anxiety and depression questionnaires at baseline? Do changes in AI-derived language markers parallel changes in clinical and self-reported outcomes following the dietary intervention? Primary outcomes / hypotheses: Does the anti-inflammatory dietary intervention produce greater reductions in anxiety and depressive symptom severity compared to the control group after 4 months? Does the intervention result in significant improvements in physical health and cognitive performance compared to the control group? Researchers will compare the anti-inflammatory diet intervention group with the control group (usual diet or standard dietary advice) to determine whether the intervention leads to superior improvements in mental, physical, and cognitive health outcomes. Participants will: Complete baseline assessments including validated questionnaires on anxiety, depression, physical health, cognitive functioning, and quality of life. Undergo structured interviews at baseline during which verbal and non-verbal language data will be recorded and analyzed using artificial intelligence-based models. Be allocated to either the anti-inflammatory dietary intervention group or the control group. Follow their assigned dietary condition for 4 months. Complete post-intervention assessments identical to baseline, including psychometric questionnaires and cognitive and physical health evaluations.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
We will use an anti-inflammatory diet to assess its impact on physical, mental and cognitive health
No intervention
Universidad of Zaragoza
Zaragoza, Zaragoza, Spain
Anxiety level (Depression, Anxiety, Stress Scale; DASS-42)
Time frame: From enrollment to the end of treatment at 16 weeks
Depression level (Depression, Anxiety, Stress Scale; DASS-42)
Time frame: From enrollment to the end of treatment at 16 weeks
SF-36
Time frame: From enrollment to the end of treatment at 16 weeks
GLUCEMIC PROFILE
Time frame: From enrollment to the end of treatment at 16 weeks
INFLAMMATORY PROFILE
Time frame: From enrollment to the end of treatment at 16 weeks
Gastrointestinal symptoms (Gastrointestinal Symptom Rating Scale)
Time frame: From enrollment to the end of treatment at 16 weeks
Physical activity (International Physical Activity Questionnaire)
We evaluate intense, moderate and soft physical activity through IPAQ questionnaire
Time frame: From enrollment to the end of treatment at 16 weeks
Sleep quality (Pittsburg Sleep Quality Index)
Time frame: From enrollment to the end of treatment at 16 weeks
Food Frequency Questionnaire
Time frame: From enrollment to the end of treatment at 16 weeks
Adherence to Mediterranean diet (MEDAS Scale)
We evaluate the adherence to the mediterranean diet through MEDAS scale
Time frame: From enrollment to the end of treatment at 16 weeks
BMI
Time frame: From enrollment to the end of treatment at 16 weeks
Weight
Time frame: From enrollment to the end of treatment at 16 weeks
CD-RISK
Time frame: From enrollment to the end of treatment at 16 weeks
LIPID PROFILE
Time frame: From enrollment to the end of treatment at 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.